Every injectable medicine and implantable device made or sold in the Kingdom must be shown to be free of pyrogenic levels of endotoxin. For QC laboratories, endotoxin testing in Saudi Arabia now means choosing between three families of method: the established Limulus amebocyte lysate (LAL) test, animal-free recombinant Factor C (rFC), and the cell-based monocyte activation test (MAT). This article compares them, explains the interference problems that cause most failed tests, and outlines how to decide which method belongs in your laboratory.
What endotoxin is and why it matters
Endotoxins are lipopolysaccharides from the outer membrane of Gram-negative bacteria. When they reach the bloodstream they trigger fever and, at higher doses, can cause shock. They are released when bacteria die, so killing bacteria does not remove the hazard; in fact sterilisation can increase free endotoxin.
Endotoxin is also heat-stable. Standard steam sterilisation does not destroy it, and removing it from glassware requires dry-heat depyrogenation at high temperature. In manufacturing it arrives on raw materials, in water, and on equipment, which is why testing runs from incoming materials to the finished product.
Limits are set per product. For parenteral drugs the endotoxin limit is calculated from a threshold pyrogenic dose and the maximum dose per kilogram of body weight. Water for injection and medical devices have their own specifications.
Method 1: Limulus amebocyte lysate (LAL)
LAL is made from the blood cells of the horseshoe crab. It contains a cascade of enzymes that clots in the presence of endotoxin, and the pharmacopoeial bacterial endotoxins test (USP <85>, Ph. Eur. 2.6.14) is built on it. It comes in three formats:
- Gel-clot: a simple positive or negative result at a defined sensitivity, useful for limit tests and confirmations.
- Kinetic turbidimetric: the increase in turbidity is measured over time and compared with a standard curve.
- Kinetic or endpoint chromogenic: a synthetic substrate releases a coloured product that is measured with a plate reader.
The strengths of LAL are its long regulatory history, its sensitivity and the depth of experience across the industry. Its weaknesses are its animal origin, lot-to-lot variability, and a second activation pathway through Factor G, which can be triggered by β-glucans from cellulose-based filters or plant-derived materials and give falsely high results.
Method 2: recombinant Factor C (rFC)
Factor C is the first enzyme in the LAL cascade and the one that responds specifically to endotoxin. Recombinant Factor C reproduces it without animal material, usually with a fluorescent substrate that is read on a plate reader.
Because it contains no Factor G pathway, rFC is not triggered by glucans. It also offers consistent supply and lot-to-lot reproducibility and supports sustainability goals around horseshoe crab populations. The European Pharmacopoeia describes it in chapter 2.6.32, and the United States Pharmacopeia has published a chapter for recombinant reagents.
Adopting rFC for an existing product still requires validation against the product matrix and, for a licensed product, the appropriate regulatory change process.
Method 3: the monocyte activation test (MAT)
MAT takes a different approach. It exposes human monocytes, from blood or a cell line, to the sample and measures the cytokines they release. Because it mimics the human fever response, MAT detects both endotoxin and non-endotoxin pyrogens, such as components of Gram-positive bacteria and fungi, which LAL and rFC cannot see.
MAT is described in Ph. Eur. 2.6.30 and is the in-vitro replacement for the rabbit pyrogen test, which European regulators are phasing out. It is particularly relevant for products where non-endotoxin pyrogens are a realistic risk, such as some biologics, vaccines and medical devices.
Comparing the three methods
| LAL | rFC | MAT | |
|---|---|---|---|
| Detects | Endotoxin | Endotoxin | Endotoxin and non-endotoxin pyrogens |
| Source | Horseshoe crab blood | Recombinant protein | Human monocytes |
| Glucan interference | Possible (Factor G) | No | No |
| Typical format | Gel-clot, turbidimetric, chromogenic | Fluorescent plate assay | Cell culture and cytokine assay |
| Main use | Routine release testing | Routine release testing, animal-free | Pyrogen testing, rabbit test replacement |
Interference: the source of most failed tests
Whichever method is used, the sample itself can distort the result. Components of the product can inhibit the reaction, hiding endotoxin, or enhance it, overstating it. Before a method is used for a product, a test for interfering factors is run: known amounts of endotoxin are spiked into the product and must be recovered within defined limits.
Interference is usually overcome by dilution. The product can be diluted up to its maximum valid dilution, calculated from the endotoxin limit, the product concentration and the sensitivity of the test. If interference persists at the maximum valid dilution, other treatments such as heat or pH adjustment may be needed.
A special case is low endotoxin recovery, seen in some biologic formulations that contain chelating agents and surfactants. Endotoxin spiked into these products can become undetectable over time, even though it is still present. The effect is investigated with hold-time studies before a method is accepted.
Choosing a method for your laboratory
A practical decision usually follows these questions:
- What does the product need? If non-endotoxin pyrogens are a risk, MAT has a role. For most small-molecule parenterals and water testing, an endotoxin-specific method is sufficient.
- Are glucans present? Products or processes that use cellulose-based filters or plant-derived materials may benefit from rFC.
- What is licensed? For marketed products, changing the method is a regulatory change and needs a validation package.
- Throughput and data integrity. Kinetic plate-based methods suit high sample volumes and integrate with laboratory software.
- Supply and sustainability. rFC offers consistent supply without animal material.
Many laboratories run more than one method: LAL or rFC for routine release and water testing, and MAT for specific products or investigations.
Endotoxin testing and regulation in Saudi Arabia
In the Kingdom, pharmaceutical products are regulated by the Saudi Food and Drug Authority (SFDA). Endotoxin requirements follow the pharmacopoeias referenced in a product's registration. Manufacturers planning to change their endotoxin method should confirm the change procedure with the SFDA before switching routine release testing.
How Arab Lab supports endotoxin testing
Lonza offers endotoxin and pyrogen testing for raw materials, in-process samples and manufactured product, meeting regulatory requirements for injectable drugs and implantable medical devices, along with MODA paperless QC software for trending results across the laboratory. Arab Lab supplies these solutions from its Riyadh office and across the UAE and Egypt. See endotoxin testing for the full solution, or send your product and current method through the contact page to discuss the options.
